Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 83

1.

Scleroderma and pulmonary hypertension complicating two pregnancies: use of neuraxial anesthesia, general anesthesia, epoprostenol and a multidisciplinary approach for cesarean delivery.

Moaveni D, Cohn J, Brodt J, Hoctor K, Ranasinghe J.

Int J Obstet Anesth. 2015 Nov;24(4):375-82. doi: 10.1016/j.ijoa.2015.05.001. Epub 2015 May 8.

PMID:
26119257
2.

Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.

Murdaca G, Spanò F, Puppo F.

Expert Opin Drug Saf. 2014 Mar;13(3):295-305. doi: 10.1517/14740338.2014.872238. Epub 2014 Jan 3. Review.

PMID:
24387049
3.

Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.

Rubenfire M, Huffman MD, Krishnan S, Seibold JR, Schiopu E, McLaughlin VV.

Chest. 2013 Oct;144(4):1282-1290. doi: 10.1378/chest.12-0653.

PMID:
23744060
4.

Effective treatment of malignant atrophic papulosis (Köhlmeier-Degos disease) with treprostinil--early experience.

Shapiro LS, Toledo-Garcia AE, Farrell JF.

Orphanet J Rare Dis. 2013 Apr 4;8:52. doi: 10.1186/1750-1172-8-52.

5.

Pulmonary arterial hypertension in the elderly-clinical characteristics and long-term survival.

Shimony A, Fox BD, Afilalo J, Rudski LG, Hirsch A, Langleben D.

Lung. 2012 Dec;190(6):645-9. doi: 10.1007/s00408-012-9425-5. Epub 2012 Oct 11.

PMID:
23064491
6.

Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.

Tamaki Z, Asano Y, Hatano M, Yao A, Kawashima T, Tomita M, Kinugawa K, Nagai R, Sato S.

Mod Rheumatol. 2012 Feb;22(1):94-9. doi: 10.1007/s10165-011-0472-1. Epub 2011 Jun 3.

PMID:
21633912
7.

Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis.

Walker KM, Pope J; Scleroderma Clinical Trials Consortium; Canadian Scleroderma Research Group.

J Rheumatol. 2011 Jul;38(7):1326-8. doi: 10.3899/jrheum.101262. Epub 2011 Apr 1.

PMID:
21459952
8.

How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?

Barst R.

Int J Clin Pract Suppl. 2010 Nov;(168):23-32. doi: 10.1111/j.1742-1241.2010.02525.x. Review.

PMID:
20939843
9.

Pulmonary capillary hemangiomatosis associated with CREST syndrome: a case report and review of the literature.

McGuire F, Kennelly T, Tillack T, Robbins M.

Respiration. 2010;80(5):435-8. doi: 10.1159/000314587. Epub 2010 May 6. Review.

PMID:
20453487
10.

Pulmonary arterial hypertension in connective tissue diseases.

Goldberg A.

Cardiol Rev. 2010 Mar-Apr;18(2):85-8. doi: 10.1097/CRD.0b013e3181cbcde7. Review.

PMID:
20160534
11.

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.

Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.

Rheumatology (Oxford). 2010 Mar;49(3):490-500. doi: 10.1093/rheumatology/kep398. Epub 2009 Dec 16.

PMID:
20015974
12.

Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.

Badesch DB, McGoon MD, Barst RJ, Tapson VF, Rubin LJ, Wigley FM, Kral KM, Raphiou IH, Crater GD.

J Rheumatol. 2009 Oct;36(10):2244-9. doi: 10.3899/jrheum.081277. Epub 2009 Sep 1.

PMID:
19723905
13.

Therapy for pulmonary arterial hypertension associated with systemic sclerosis.

Mathai SC, Hassoun PM.

Curr Opin Rheumatol. 2009 Nov;21(6):642-8. doi: 10.1097/BOR.0b013e3283307dc8. Review.

14.

Updated evidence-based treatment algorithm in pulmonary arterial hypertension.

Barst RJ, Gibbs JS, Ghofrani HA, Hoeper MM, McLaughlin VV, Rubin LJ, Sitbon O, Tapson VF, Galiè N.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S78-84. doi: 10.1016/j.jacc.2009.04.017. Review.

15.

Updated clinical classification of pulmonary hypertension.

Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R.

J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-54. doi: 10.1016/j.jacc.2009.04.012. Review.

16.

Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V.

Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. doi: 10.1093/rheumatology/kep107. Review.

PMID:
19487219
17.

[Double-lung transplantation in 15 patients with pulmonary hypertension].

López-Meseguer M, Román A, Monforte V, Bravo C, Solé J, Morell F.

Arch Bronconeumol. 2009 Aug;45(8):366-70. doi: 10.1016/j.arbres.2008.11.007. Epub 2009 May 2. Spanish.

18.

[Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].

Sicińska J, Rudnicka L.

Pol Merkur Lekarski. 2008 Aug;25(146):196-200. Review. Polish.

PMID:
18942347
19.

Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.

Bendayan D, Shitrit D, Kramer MR.

Respirology. 2008 Nov;13(6):916-8. doi: 10.1111/j.1440-1843.2007.01176.x.

PMID:
18811891
20.

Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension.

Zlupko M, Harhay MO, Gallop R, Shin J, Archer-Chicko C, Patel R, Palevsky HI, Taichman DB.

Respir Med. 2008 Oct;102(10):1431-8. doi: 10.1016/j.rmed.2008.04.016. Epub 2008 Jul 9.

Supplemental Content

Loading ...
Support Center